What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids) growth hormone secretagogue (GHS) developed by NovoNordisk’s research division in the 1990s. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂, where Aib is α-aminoisobutyric acid (a non-proteinogenic amino acid) and D-2-Nal is D-2-naphthylalanine. Molecular weight is approximately 712 Da.
Ipamorelin is one of several GHS compounds studied as potential alternatives to exogenous growth hormone therapy, motivated by the desire to stimulate endogenous pulsatile GH release (the physiological pattern) rather than achieve the sustained levels produced by exogenous administration.
Evidence snapshot
Status: Preclinical; one discontinued Phase 2 program. Studies referenced: 70+. Human RCTs: Limited and discontinued. Regulatory approval: None in EU, US, or UK.
Mechanism: GHSR-1a agonism with apparent selectivity
Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a) — the same receptor targeted by the endogenous peptide ghrelin and by synthetic ghrelin mimetics. Activation of GHSR-1a on pituitary somatotrophs stimulates GH release.
What distinguishes ipamorelin from earlier GHS compounds (GHRP-6, GHRP-2, hexarelin) is its apparent selectivity. In direct comparative studies, ipamorelin produced GH release without significant increases in cortisol, ACTH, or prolactin — endocrine effects that had been a recurring problem for earlier GHS molecules.
The mechanism of this selectivity is not fully resolved. One proposal: ipamorelin’s shorter half-life at the receptor limits the duration of GHSR-1a activation, which is sufficient to trigger GH release but not the secondary endocrine cascades that longer-acting agonists produce.
Effects on GH pulsatility
In rodent and pig models, ipamorelin has been reported to:
- Increase GH pulse amplitude without significantly increasing pulse frequency.
- Produce dose-dependent GH release with a defined duration of action.
- Avoid tachyphylaxis in short-term studies (no acute desensitisation).
- Increase IGF-1 levels in vivo, downstream of GH release.
Effects on gastric motility and appetite
Because GHSR-1a is also expressed in the hypothalamus and the gastric NPY system, ipamorelin’s effect on food intake is sometimes studied. In rat models, ipamorelin produces less orexigenic effect than ghrelin or longer-acting GHS peptides — consistent with its shorter receptor residence time.
What the (limited) human data shows
Ipamorelin reached a single Phase 2 clinical development program in post-operative ileus (bowel recovery after surgery) before the program was discontinued. The published data from that program is limited to conference abstracts and early-phase pharmacokinetic studies.
Beyond the discontinued Phase 2 program, no large, peer-reviewed human RCTs of ipamorelin have been published. The compound has been available as a research peptide for off-label use since the mid-2000s, and the literature has accumulated mostly from non-clinical sources.
Comparison with other GHS molecules
Compared with earlier GHS peptides:
- GHRP-6 / GHRP-2 — produce GH release but with significant appetite stimulation and cortisol/prolactin effects.
- Hexarelin — potent GH release but with rapid tachyphylaxis and cortisol effects at higher doses.
- MK-677 (ibutamoren) — orally bioavailable non-peptide GHSR agonist with longer action; produces GH release but also increases appetite, cortisol, and HGH-axis feedback.
In head-to-head comparisons, ipamorelin typically shows the cleanest GH-selectivity profile, but at the cost of smaller peak GH release and shorter duration of action.
Limits of the evidence
- Discontinued development. Ipamorelin’s clinical development was halted, and the Phase 2 data was never fully published.
- No large human RCTs. The clinical evidence base is essentially preclinical.
- Off-label human use. Widely available as a research peptide, with extensive off-label use despite no approved human indication.
- Selectivity mechanism unclear. The clean endocrine profile is not yet fully explained at the molecular level.
The bottom line
Ipamorelin’s preclinical profile is genuinely interesting: a peptide GHS agonist with apparent selectivity for GH release over cortisol/prolactin, and a shorter action profile that better resembles physiological pulsatility. Whether this translates to clinical utility in any human indication is unknown — the clinical development was halted before meaningful Phase 2/3 data was generated.
Off-label ipamorelin administration is widespread in the “biohacking” and anti-ageing contexts, but lacks the rigorous clinical evidence to support specific protocols.